Frontier Biotechnologies, Inc. (China) (688221) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Frontier Biotechnologies, Inc. (China)

Why is Frontier Biotechnologies, Inc. (China) ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 25.68% and Operating profit at 2.96% over the last 5 years

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 82.09%, its profits have risen by 56.6%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Frontier Biotechnologies, Inc. (China) should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Frontier Biotechnologies, Inc. (China) for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Frontier Biotechnologies, Inc. (China)

92.99%

3.06

73.57%

China Shanghai Composite

21.43%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

50.61%

EBIT Growth (5y)

14.29%

EBIT to Interest (avg)

-95.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

989

Industry P/E

Price to Book Value

3.37

EV to EBIT

-280.44

EV to EBITDA

166.61

EV to Capital Employed

4.09

EV to Sales

8.87

PEG Ratio

9.69

Dividend Yield

ROCE (Latest)

-1.46%

ROE (Latest)

0.34%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

43What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 52.67 MM

ROCE(HY)

Highest at 0.31%

RAW MATERIAL COST(Y)

Fallen by -300.22% (YoY

NET SALES(Q)

Highest at CNY 297.13 MM

OPERATING PROFIT(Q)

Highest at CNY 220.52 MM

OPERATING PROFIT MARGIN(Q)

Highest at 74.22 %

PRE-TAX PROFIT(Q)

Highest at CNY 227.37 MM

NET PROFIT(Q)

Highest at CNY 227.37 MM

EPS(Q)

Highest at CNY 0.61

-3What is not working for the Company

CASH AND EQV(HY)

Lowest at CNY 1,442.86 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.45 times

Here's what is working for Frontier Biotechnologies, Inc. (China)

Net Sales

At CNY 297.13 MM has Grown at 948.89%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 227.37 MM has Grown at 617.75%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 227.37 MM has Grown at 617.75%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Cash Flow

Highest at CNY 52.67 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

Highest at CNY 297.13 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit

Highest at CNY 220.52 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin

Highest at 74.22 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CNY 227.37 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 227.37 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.61

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -300.22% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Frontier Biotechnologies, Inc. (China)

Cash and Eqv

Lowest at CNY 1,442.86 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 1.45 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Non Operating Income

Highest at CNY 0.04 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income